| # | Title | Journal | Year | Citations |
|---|
| 1 | Romosozumab Treatment in Postmenopausal Women with Osteoporosis | New England Journal of Medicine | 2016 | 1,099 |
| 2 | Maintenance Therapy with Certolizumab Pegol for Crohn's Disease | New England Journal of Medicine | 2007 | 1,033 |
| 3 | Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis | New England Journal of Medicine | 2017 | 901 |
| 4 | Individual intestinal symbionts induce a distinct population of RORγ + regulatory T cells | Science | 2015 | 707 |
| 5 | Microbial bile acid metabolites modulate gut RORγ+ regulatory T cell homeostasis | Nature | 2020 | 568 |
| 6 | Developing Irreversible Inhibitors of the Protein Kinase Cysteinome | Chemistry and Biology | 2013 | 563 |
| 7 | Mining the Human Gut Microbiota for Immunomodulatory Organisms | Cell | 2017 | 554 |
| 8 | Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins | Cell Biology and Toxicology | 2012 | 529 |
| 9 | New avenues for anti-epileptic drug discovery and development | Nature Reviews Drug Discovery | 2013 | 506 |
| 10 | Hybridization Chain Reaction Amplification of MicroRNA Detection with a Tetrahedral DNA Nanostructure-Based Electrochemical Biosensor | Analytical Chemistry | 2014 | 460 |
| 11 | Single‐Particle Tracking and Modulation of Cell Entry Pathways of a Tetrahedral DNA Nanostructure in Live Cells | Angewandte Chemie - International Edition | 2014 | 430 |
| 12 | Multicenter Double‐Blind, Randomized, Placebo‐Controlled Trial of Levetiracetam as Add‐On Therapy in Patients with Refractory Partial Seizures | Epilepsia | 2000 | 415 |
| 13 | Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA) | Annals of the Rheumatic Diseases | 2014 | 393 |
| 14 | Smart Drug Delivery Nanocarriers with Self‐Assembled DNA Nanostructures | Advanced Materials | 2013 | 378 |
| 15 | Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study | Annals of the Rheumatic Diseases | 2014 | 378 |
| 16 | Programmable Engineering of a Biosensing Interface with Tetrahedral DNA Nanostructures for Ultrasensitive DNA Detection | Angewandte Chemie - International Edition | 2015 | 350 |
| 17 | Imaging synaptic density in the living human brain | Science Translational Medicine | 2016 | 343 |
| 18 | Identifying species of symbiont bacteria from the human gut that, alone, can induce intestinal Th17 cells in mice | Proceedings of the National Academy of Sciences of the United States of America | 2016 | 331 |
| 19 | The epidemiology of drug‐resistant epilepsy: A systematic review and meta‐analysis | Epilepsia | 2018 | 316 |
| 20 | Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial | Lancet, The | 2017 | 313 |
| 21 | Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss | Annals of the Rheumatic Diseases | 2016 | 289 |
| 22 | Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study | Annals of the Rheumatic Diseases | 2018 | 279 |
| 23 | Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study | Annals of the Rheumatic Diseases | 2014 | 266 |
| 24 | Imaging robust microglial activation after lipopolysaccharide administration in humans with PET | Proceedings of the National Academy of Sciences of the United States of America | 2015 | 265 |
| 25 | The Deubiquitinase OTULIN Is an Essential Negative Regulator of Inflammation and Autoimmunity | Cell | 2016 | 259 |
| 26 | Five computational developability guidelines for therapeutic antibody profiling | Proceedings of the National Academy of Sciences of the United States of America | 2019 | 221 |
| 27 | Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: A phase III randomized, double‐blind, placebo‐controlled trial | Epilepsia | 2014 | 217 |
| 28 | ABodyBuilder: Automated antibody structure prediction with data–driven accuracy estimation | MAbs | 2016 | 208 |
| 29 | Commonalities in epileptogenic processes from different acute brain insults: Do they translate? | Epilepsia | 2018 | 206 |
| 30 | Increased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECiSE 2 Randomized Maintenance Trial Data | American Journal of Gastroenterology | 2010 | 201 |
| 31 | A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis | Journal of Clinical Endocrinology and Metabolism | 2018 | 195 |
| 32 | Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation | Annals of the Rheumatic Diseases | 2018 | 191 |
| 33 | Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: Results from a double‐blind, randomized, placebo‐controlled trial | Epilepsia | 2014 | 190 |
| 34 | Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials | Arthritis and Rheumatology | 2017 | 189 |
| 35 | A randomized, double‐blind, placebo‐controlled, multicenter, parallel‐group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial‐onset seizures | Epilepsia | 2015 | 188 |
| 36 | A multi-crystal method for extracting obscured crystallographic states from conventionally uninterpretable electron density | Nature Communications | 2017 | 186 |
| 37 | PI3K p110δ regulates T-cell cytokine production during primary and secondary immune responses in mice and humans | Blood | 2010 | 174 |
| 38 | A systematic review of the safety profile of levetiracetam: a new antiepileptic drug | Epilepsy Research | 2001 | 170 |
| 39 | Diagnostic methods and treatment options for focal cortical dysplasia | Epilepsia | 2015 | 167 |
| 40 | Planning experiments: Updated guidance on experimental design and analysis and their reporting III | British Journal of Pharmacology | 2022 | 167 |
| 41 | Observed Antibody Space: A Resource for Data Mining Next-Generation Sequencing of Antibody Repertoires | Journal of Immunology | 2018 | 165 |
| 42 | Design of protein-binding proteins from the target structure alone | Nature | 2022 | 164 |
| 43 | Hippocampal subregion-specific microRNA expression during epileptogenesis in experimental temporal lobe epilepsy | Neurobiology of Disease | 2014 | 163 |
| 44 | Current understanding of the mechanism of action of the antiepileptic drug lacosamide | Epilepsy Research | 2015 | 163 |
| 45 | Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial | Journal of the American Academy of Dermatology | 2018 | 163 |
| 46 | Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus | Nature Genetics | 2012 | 162 |
| 47 | Drug metabolism and disposition in children | Fundamental and Clinical Pharmacology | 2003 | 160 |
| 48 | SAbPred: a structure-based antibody prediction server | Nucleic Acids Research | 2016 | 155 |
| 49 | A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials | Epilepsy and Behavior | 2003 | 152 |
| 50 | Understanding Cryptic Pocket Formation in Protein Targets by Enhanced Sampling Simulations | Journal of the American Chemical Society | 2016 | 151 |
